Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer von Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., Baird, R. D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O. E., Ferguson, V., Seckl, M. J.

Volltext

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer von Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., Baird, R. D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O. E., Ferguson, V., Seckl, M. J.

Volltext

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours von Arkenau, H.-T., Italiano, A., Mak, G., Toulmonde, M., Baird, R.D., Garcia-Corbacho, J., Plummer, R., Flynn, M., Forster, M., Wilson, R.H., Tosi, D., Adenis, A., Donaldson, K., Posner, J., Kawabata, I., Arimura, A., Deva, S., Spicer, J.

Volltext

Drug resistance reversal—are we getting closer? von Baird, R.D, Kaye, S.B

Volltext

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy re... von Hamilton, E., Oliveira, M., Turner, N., García-Corbacho, J., Hernando, C., Ciruelos, E.M., Kabos, P., Ruiz-Borrego, M., Armstrong, A., Patel, M.R., Vaklavas, C., Twelves, C., Boni, V., Incorvati, J., Brier, T., Gibbons, L., Klinowska, T., Lindemann, J.P.O., Morrow, C.J., Sykes, A., Baird, R.D.

Volltext

Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications von Baird, R.D, Carroll, J.S

Volltext

Post-operative endophthalmitis: the application of hazard analysis critical control points (HACCP) to an infection control problem von Baird, D.R., Henry, M., Liddell, K.G., Mitchell, C.M., Sneddon, J.G.

Volltext

The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials von Vitfell-Pedersen, J, Yap, T A, Moreno, V, Baird, R D, Khan, A Z, Barton, D P J, Kaye, S B

Volltext

A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens von Amyes, S. G. B., Baird, D. R., Crook, D. W., Gillesple, S. H., Howard, A. J., Oppenhiem, B. A., Pedler, S. J., Paull, A., Tompkins, D. S., Lawrie, S. A.

Volltext

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer von Coombes, RC, Badman, PD, Lozano-Kuehne, JP, Liu, X, Macpherson, IR, Zubairi, I, Baird, RD, Rosenfeld, N, Garcia-Corbacho, J, Cresti, N, Plummer, R, Armstrong, A, Allerton, R, Landers, D, Nicholas, H, McLellan, L, Lim, A, Mouliere, F, Pardo, OE, Ferguson, V, Seckl, MJ

Volltext

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib von Coombes, RC, Howell, S, Lord, SR, Kenny, L, Mansi, J, Mitri, Z, Palmieri, C, Chap, LI, Richards, P, Gradishar, W, Sardesai, S, Melear, J, O'Shaughnessy, J, Ward, P, Chalasani, P, Arkenau, T, Baird, RD, Jeselsohn, R, Ali, S, Clack, G, Bahl, A, McIntosh, S, Krebs, MG

Volltext

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib von Charles Coombes, R, Howell, S, Lord, SR, Kenny, L, Mansi, J, Mitri, Z, Palmieri, C, Chap, LI, Richards, P, Gradishar, W, Sardesai, S, Melear, J, O'Shaughnessy, J, Ward, P, Chalasani, P, Arkenau, T, Baird, RD, Jeselsohn, R, Ali, S, Clack, G, Bahl, A, McIntosh, S, Krebs, MG

Volltext

Results of the Phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer von Coombes, R, Badman, P, Lozano-Kuehne, JP, Liu, X, Macpherson, IR, Baird, RD, Rosenfeld, N, Garcia-Corbacho, J, Cresti, N, Plummer, R, Armstrong, A, Allerton, R, Landers, D, Nicholas, H, McLellan, L, Lim, A, Mouliere, F, Pardo, OP, Seckl, MJ

Volltext

Hereditary and Sporadic Cancers Respond to Niraparib

Volltext

Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors von Brana, Irene, Massard, Christophe, Baird, Richard D., Opdam, Frans, Schlenk, Richard F., De Petris, Luigi, Vernieri, Claudio, Chavarria, Elena, Garralda, Elena, van der Noll, Ruud, Vivancos, Ana, Wessels, Lodewyk F. A., Martin, Jose-Ezequiel, Tamborero, David, Dienstmann, Rodrigo, Meijer, Gerrit A., Muñoz, Susana, Piris-Giménez, Alejandro, Calvo, Fabien, Rodon, Jordi

Volltext

Handbook of culture media for food and water microbiology von Corry, Janet E. L, Curtis, G. D. W, Baird, R. M. (Rosamund M.)

Volltext

Abstract OT1-01-07: PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast ca... von Kumar, SS, Benson, J, McIntosh, S, King, P, Dougall, G, Kateb, A, Vallier, A-L, Jones, L, Qian, W, Provenzano, E, Caldas, C, Pantziarka, P, Carroll, J, Baird, RD

Volltext

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer von Macpherson, IR, Spiliopoulou, P, Rafii, S, Saggese, M, Baird, RD, Garcia-Corbacho, J, Italiano, A, Bonneterre, J, Campone, M, Cresti, N, Posner, J, Takeda, Y, Arimura, A, Spicer, J

Volltext

Carotid patch angioplasty: Immediate and long-term results von Rosenthal, David, Archie, Joseph P., Garcia-Rinaldi, Raul, Seagraves, M.Annette, Baird, David R., McKinsey, James F., Lamis, Pano A., Clark, Michael D., Erdoes, Luke S., Whitehead, Travis, Laszlo Pallos, L.

Volltext

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience von Alam, S. M., Fehrmann, R. S., Olmos, D., Shah, K., Puglisi, M., Sarker, D., Brunetto, A., Postel-Vinay, S., Baird, R. D., Molife, L. R.

Volltext